Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Investments (2020 - 2025)

Bioventus (BVS) has disclosed Long-Term Investments for 6 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 21.19% year-over-year to $2.3 million, compared with a TTM value of $2.3 million through Dec 2025, up 21.19%, and an annual FY2025 reading of $2.3 million, up 21.19% over the prior year.
  • Long-Term Investments was $2.3 million for Q4 2025 at Bioventus, up from $2.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $78.5 million in Q3 2022 and bottomed at $1.7 million in Q2 2025.
  • Average Long-Term Investments over 5 years is $11.0 million, with a median of $2.9 million recorded in 2022.
  • The sharpest move saw Long-Term Investments skyrocketed 36.17% in 2022, then plummeted 91.67% in 2023.
  • Year by year, Long-Term Investments stood at $16.8 million in 2021, then tumbled by 84.37% to $2.6 million in 2022, then grew by 19.84% to $3.1 million in 2023, then plummeted by 39.76% to $1.9 million in 2024, then increased by 21.19% to $2.3 million in 2025.
  • Business Quant data shows Long-Term Investments for BVS at $2.3 million in Q4 2025, $2.3 million in Q3 2025, and $1.7 million in Q2 2025.